Jazz Pharmaceuticals (JAZZ) revenue

Revenue · fiscal 2025
$4.27B

Jazz Pharmaceuticals (JAZZ) reported revenue of $4.27B in fiscal 2025 (the year ended December 31, 2025). That is 4.9% higher than the $4.07B of fiscal 2024. Figures as of 18 Nov 2026, 09:47 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Revenue, fiscal 2025
$4.27B
Change on fiscal 2024
+4.9%
Growth, 5 years
+12.5% a year
Growth, 10 years
+12.4% a year
Highest on record
$4.27Bfiscal 2025
Lowest on record
$128.45Mfiscal 2009
Fiscal years on record
172009–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Jazz Pharmaceuticals revenue, in more detail

Over the five fiscal years to 2025 revenue grew at a compound 12.5% a year; over ten years the rate was 12.4% a year. Across the 17 fiscal years on record (2009–2025), the highest was $4.27B in fiscal 2025 and the lowest $128.45M in fiscal 2009.

History · 17 fiscal years

Revenue by fiscal year

Jazz Pharmaceuticals revenue, year by year

Jazz Pharmaceuticals (JAZZ) revenue by fiscal year
Fiscal yearRevenueChangeYear ended
2025$4.27B 4.9% up
2024$4.07B 6.1% up
2023$3.83B 4.8% up
2022$3.66B 18.3% up
2021$3.09B 30.9% up
2020$2.36B 9.3% up
2019$2.16B 14.3% up
2018$1.89B 16.8% up
2017$1.62B 8.8% up
2016$1.49B 12.3% up
2015$1.32B 13.0% up
2014$1.17B 34.4% up
2013$872.42M 48.9% up
2012$585.98M 115.2% up
2011$272.28M 56.7% up
2010$173.78M 35.3% up
2009$128.45M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

Revenue at health care companies of similar size

Revenue of Jazz Pharmaceuticals and comparable companies
CompanyRevenueFiscal year
Neurocrine Biosciences NBIX$2.86B2025
Ascendis Pharma ASND€720.13M2025
ICON ICLR$8.25B2025
Jazz Pharmaceuticals JAZZ$4.27B2025
Solventum SOLV$8.33B2025
BridgeBio Pharma BBIO$502.08M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on JAZZ

Jazz Pharmaceuticals, figure by figure

Jazz Pharmaceuticals (JAZZ) overview: price, valuation and scorecardAll health care companies by market value

Jazz Pharmaceuticals revenue: questions and answers

What is Jazz Pharmaceuticals's revenue?

Jazz Pharmaceuticals (JAZZ) reported revenue of $4.27B in fiscal 2025 (the year ended December 31, 2025). That is 4.9% higher than the $4.07B of fiscal 2024.

What is the growth rate of Jazz Pharmaceuticals's revenue?

Over the five fiscal years to 2025 revenue grew at a compound 12.5% a year; over ten years the rate was 12.4% a year.

What are the highest and lowest revenue figures on record for Jazz Pharmaceuticals?

Across the 17 fiscal years on record (2009–2025), the highest was $4.27B in fiscal 2025 and the lowest $128.45M in fiscal 2009.

How is Jazz Pharmaceuticals's revenue calculated?

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Jazz Pharmaceuticals it is on record here for 17 fiscal years, 2009 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Jazz Pharmaceuticals (JAZZ) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/JAZZ/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.